Key Takeaways
- • Apollo Global Management is in active negotiations to acquire Johnson & Johnson's DePuy Synthes orthopaedics business for approximately $20 billion, competing against multiple other private equity bidders.
- • DePuy Synthes generated $9.3 billion in revenue in 2025 and manufactures medical devices for orthopedic procedures including hip and knee replacements, representing a significant asset in the medical device sector.
- • J&J announced its intention to separate the orthopaedics business in October 2025, with the company targeting completion of the separation by mid-2027; an agreement with Apollo could be reached within several weeks, though discussions remain preliminary.
- • The company is evaluating multiple strategic alternatives beyond an Apollo transaction, including a sale to other bidders or a potential spin-off as an independently listed company, with CFO Joseph Wolk emphasizing the need to maximize shareholder value.
- • Representatives from both Apollo and J&J have declined to comment on the discussions, and the negotiations remain subject to change with no certainty of completion.
Summary
Apollo Global Management is negotiating to acquire Johnson & Johnson's DePuy Synthes orthopaedics division in a deal valued at approximately $20 billion, according to Bloomberg reporting citing unnamed sources familiar with the matter. The private equity firm represents one of several buyout groups that have expressed interest in the business unit. If finalized, an agreement could be reached within the next several weeks, though discussions remain ongoing and could ultimately terminate without a transaction.
J&J announced plans to separate its orthopaedics operations in October 2025 as part of a broader strategic review. The company has been evaluating multiple structural options for DePuy Synthes, including an outright sale to a third party, a private equity transaction, or a spin-off into an independently listed public company. According to CFO Joseph Wolk's July commentary, J&J remains focused on identifying a structure that will maximize shareholder value while positioning DePuy Synthes for sustained long-term growth. The company has targeted completion of the separation process by mid-2027.
DePuy Synthes is a substantial medical device manufacturer with diversified revenue streams across orthopedic surgery. The unit generated $9.3 billion in revenue during 2025 and produces devices utilized in hip replacements, knee replacements, and related orthopedic procedures. The business's scale and established market position in elective surgical markets have attracted competitive interest from the private equity community.
Both Apollo and J&J declined to comment on the reported discussions, citing standard confidentiality protocols. The preliminary nature of negotiations and multiple competing alternatives underscore the fluid status of the transaction process. Investors should monitor announcements regarding deal progress, regulatory clearance timing, and the potential for alternative transaction structures that could affect valuation and transaction terms.
J&J announced plans to separate its orthopaedics operations in October 2025 as part of a broader strategic review. The company has been evaluating multiple structural options for DePuy Synthes, including an outright sale to a third party, a private equity transaction, or a spin-off into an independently listed public company. According to CFO Joseph Wolk's July commentary, J&J remains focused on identifying a structure that will maximize shareholder value while positioning DePuy Synthes for sustained long-term growth. The company has targeted completion of the separation process by mid-2027.
DePuy Synthes is a substantial medical device manufacturer with diversified revenue streams across orthopedic surgery. The unit generated $9.3 billion in revenue during 2025 and produces devices utilized in hip replacements, knee replacements, and related orthopedic procedures. The business's scale and established market position in elective surgical markets have attracted competitive interest from the private equity community.
Both Apollo and J&J declined to comment on the reported discussions, citing standard confidentiality protocols. The preliminary nature of negotiations and multiple competing alternatives underscore the fluid status of the transaction process. Investors should monitor announcements regarding deal progress, regulatory clearance timing, and the potential for alternative transaction structures that could affect valuation and transaction terms.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.